UNSPSC 51131663: Dabigatran etexilate

This classification denotes an anticoagulant agent, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 2E18WX195X. European Medicines Agency schedules Dabigatran etexilate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB20521. Dabigatran etexilate generally arises in the molecular formula C34H41N7O5.

UNSPSC 51131663 Dabigatran etexilate is a Commodity code tracking a specific anticoagulant pharmaceutical, but recent state and local procurement activity tagged under this code does not reflect pharmaceutical procurement. Sourcewell, a Minnesota local government cooperative, posted RFP #061626 on May 12, 2026 with a June 16, 2026 response deadline to procure law enforcement equipment on behalf of participating counties and public entities across the United States and Canada. The solicitation scope—law enforcement equipment—bears no relationship to dabigatran etexilate, a blood thinner used in clinical settings. This code shows no relevant recent activity in state and local procurement of the pharmaceutical it nominally describes.

The mismatch between code and solicitation suggests either a tagging error in the source data or that dabigatran procurement under this Commodity code does not currently generate activity in the state and local contracting channels tracked here. No state or local health departments, correctional systems, or other public healthcare purchasers posted opportunities for dabigatran etexilate during the period represented in the available records. Absent supporting evidence of actual pharmaceutical procurement under this code, the signal is that dabigatran acquisition—whether through group purchasing organizations, prime vendors, or direct hospital and clinic contracts—does not surface as discrete solicitations at the state and local level in this dataset.